In 'The Burden of Alzheimer's Disease Agitation: Impact on Patients, Caregivers, and Quality of Life,' the expert neurologists examined the following critical questions: What is the impact that Alzheimer's disease agitation has on patients, as well as their caregivers, and what is the necessary education? How can it impact quality of life and impact families?
In this episode, 'Closing the Recognition Gap: Underdiagnosis, Patient Education, and Treatment Goals in Alzheimer's Disease Agitation,' the expert neurologists explored the following questions: Do you believe that Alzheimer's disease agitation is currently underdiagnosed? How are you educating patients and families? What are the treatment goals for patients with Alzheimer's disease agitation?
Kavita Nair leads the discussion on defining Alzheimer's disease agitation.
Alireza Atri introduces mild behavioral impairment as an early-emerging framework for behavioral changes preceding formal dementia diagnosis.
In 'Non-Pharmacologic Approaches to Alzheimer's Disease Agitation: Interventions, Best Practices, and Case Examples,' the expert neurologists examined the following critical questions: Before we get into the medications used to treat Alzheimer's disease agitation, what are the non-pharmacologic options and their respective roles? What are best practices for educating patients and caregivers on these and some case examples?
In this episode, 'Traditional Pharmacologic Therapies for Alzheimer's Disease Agitation: Mechanisms, Evidence, and Adverse Events,' the expert neurologists explored the following questions: What are the traditional therapies such as antipsychotics used in the management of patients with Alzheimer's disease agitation and their respective mechanisms of action? What has the data demonstrated with these therapies? What are the adverse events seen with these therapies? When are you utilizing dose reductions with these therapies?
In 'Brexpiprazole and Dextromethorphan-Buproprion: Mechanisms of Action and Key Clinical Trial Data for Approved Alzheimer's Disease Agitation Therapies,' the expert neurologists examined the following critical questions: Brexpiprazole was approved by the Food and Drug Administration (FDA) in 2023 and dextromethorphan/buproprion in 2026 for the treatment of Alzheimer's disease agitation. What are the mechanisms of action of these therapies? What were the key safety and efficacy results seen in the clinical trials?
In this episode, 'Comparing the Two Approved Therapies: Dextromethorphan-Bupropion and Brexpiprazole in Alzheimer's Disease Agitation,' the expert neurologists explored the following question: What were the key safety and efficacy results that led to its approval and how do they compare with brexpiprazole's?
In 'Choosing Between Approved Therapies: Differentiation, Sequencing, and Black Box Warning Navigation in Alzheimer's Disease Agitation,' the expert neurologists examined the following critical questions: In your practice, how are you differentiating antipsychotic therapies from dextromethorphan-bupropion for patients with Alzheimer's disease agitation? With the introduction of 2 Food and Drug Administration (FDA)-approved therapies in the last few years, how are you sequencing treatments in patients with Alzheimer's disease agitation? How are you navigating black box warnings with certain therapies?
In the final episode, 'Access, Coverage, and Final Reflections on Managing Alzheimer's Disease Agitation,' the panelists explored the following critical questions: How has insurance coverage been with the Food and Drug Administration (FDA)-approved therapies for Alzheimer's disease agitation? What are best practices in working with insurance providers to get coverage for patients?
